Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B
Tune Therapeutics is a Duke University start-up and Duke Capital Partners portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
Uplizna, an antibody therapy for immune diseases, is based on technology licensed from Duke University, developed by the late Dr. Thomas Tedder (Immunology, SOM) and colleagues.
EydisBio Receives FDA Orphan Drug Designation for TAK1 Inhibitor for the Treatment of Systemic Sclerosis
EydisBio is a start-up founded by Professor Timothy Haystead (P&CB, SOM) focusing on the treatment of autoimmune and inflammatory diseases.
Duke Inventions Bring $82.6M in Revenue and Launch 6 New Start-Ups
$82.6M in revenue. 94 patents issued. 302 new invention disclosures. In a down year for new disclosures, OTC focuses on investing in the future.
Sparta Biomedical Reports Treatment of First Patients with Breakthrough Device, Ormi
Sparta Biomedical, a Duke start-up and Duke Capital Partners portfolio company, was founded around technology developed by lead inventor Professor Benjamin Wiley (Chemistry, Trinity), along with Professor Ken Gall (MEMS, Pratt), Professor Matt Becker (Chemistry, Trinity), and colleagues.
Basking Biosciences Doses First Patients in Phase 2 Clinical Trial of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke
Basking Biosciences, a start-up out of the lab of Professor Bruce Sullenger (Surgery, SOM), is developing a next-generation treatment for acute ischemic stroke.
Adaptin Bio Announces FDA Clearance of IND Application for APTN-101 in Glioblastoma
Adaptin Bio is a Duke start-up based around glioblastoma-related technologies developed in the lab of Dr. John Sampson (Neurosurgery, SOM).
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
Lindy Biosciences is a Duke University start-up run by CEO Deborah Bitterfield (PhD MEMS, Pratt) based on technology developed in the lab of Professor Emeritus David Needham (MEMS, Pratt).
Carpe, a Duke-founded Startup, Acquired by Topspin Consumer Partners
Founded by a Duke and UNC undergrad duo in 2015, Carpe creates antiperspirant solutions for consumers.